Back to top
more

Sanofi (SNY)

(Real Time Quote from BATS)

$56.24 USD

56.24
174,273

-0.08 (-0.14%)

Updated Aug 28, 2024 11:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Amgen Looking to Broaden Leukemia Drug Blincyto's Label

by Zacks Equity Research

Biotech major Amgen Inc. (AMGN) announced that it has submitted a supplemental biologics license application (sBLA) to the FDA for its leukemia immunotherapy Blincyto.

    Arpita Dutt headshot

    Pharma Stock Roundup: Allergan, GSK Top 4Q Earnings, Praluent Breather for Sanofi

    by Arpita Dutt

    Key highlights this week include earnings results from Allergan (AGN) and Glaxo, Sanofi's update regarding Praluent and Teva's ongoing woes.

      Sheraz Mian headshot

      Top Analyst Reports for Morgan Stanley, GM & Prudential

      by Sheraz Mian

      Today's Research Daily features new research reports on 16 major stocks, including Morgan Stanley (MS), General Motors (GM), and Prudential (PRU).

        Regeneron (REGN) Misses on Q4 Earnings & Sales, View Bleak

        by Zacks Equity Research

        Regeneron Pharmaceuticals, Inc. (REGN) reported disappointing results for the fourth quarter of 2016. The outlook for 2017 did not give investors anything to cheer for either.

          Alnylam (ALNY) Q3 Loss Narrower than Expected, Revenues Rise

          by Zacks Equity Research

          Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.32 per share in the fourth quarter of 2016, narrower than both the Zacks Consensus Estimate loss of $1.35 and the year-ago loss of $1.07.

            Sanofi (SNY) Q4 Earnings In Line; Can Sell Praulent for Now

            by Zacks Equity Research

            Sanofi (SNY) reported fourth-quarter 2016 earnings of 67 cents per American depositary share, which was in line with the Zacks Consensus Estimate.

              Regeneron (REGN) Q4 Earnings: Will the Stock Disappoint?

              by Zacks Equity Research

              Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release fourth-quarter 2016 results on Feb 9, before the opening bell.

                Drug Stock Q4 Earnings to Watch on Feb 8: AGN, GSK & More

                by Zacks Equity Research

                How will these four drug stocks, AGN, GSK, ALNY and SNY, which are all scheduled to report Q4 results on Feb 8, fare this earnings season?

                  Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study

                  by Zacks Equity Research

                  Amgen Inc. (AMGN) reported fourth-quarter 2016 earnings of $2.89 per share, beating the Zacks Consensus Estimate of $2.77 by 4.3% .

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Pfizer, Merck, LLY Report Results, Teva Hit by Copaxone Ruling

                    by Arpita Dutt

                    Key highlights this week include a court ruling in the Copaxone patent infringement lawsuit and earnings results from companies like Pfizer (PFE).

                      SanofiRegeneron Sarilumab Approved in Canada for Arthritis

                      by Zacks Equity Research

                      Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced that their pipeline candidate, sarilumab, has been approved in Canada for the treatment of adult patients with moderate-to-severely active rheumatoid arthritis (RA).

                        Will Amgen (AMGN) Keep the Earnings Streak Alive in Q4?

                        by Zacks Equity Research

                        We expect biotech major Amgen Inc. (AMGN) to beat expectations when it reports fourth-quarter 2016 and full-year results on Feb 2.

                          Sanofi Diabetes Drug Suliqua Wins EU Marketing Approval

                          by Zacks Equity Research

                          Sanofi (SNY) announced that the European Commission has granted marketing authorization to its once-daily injection, Suliqua a combination of diabetes drugs Lantus and lixisenatide for the treatment of diabetes.

                            Key FDA Events to Watch Out for in Q1

                            by Zacks Equity Research

                            Two important regulatory events scheduled in the first quarter of 2017.

                              Sanofi, ImmuNext Ink Deal, Focus on Autoimmune Diseases

                              by Zacks Equity Research

                              Sanofi (SNY) announced an agreement with ImmuNext, Inc. for the development of a novel antibody to treat a range of autoimmune diseases including lupus and multiple sclerosis.

                                Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit

                                by Zacks Equity Research

                                Amgen Inc. (AMGN) announced a new six-year sourcing and supply agreement with DaVita Inc. (DVA) to supply Epogen and Aranesp to meet the latter???s requirements.

                                  Arpita Dutt headshot

                                  The FDA Approved Fewer Drugs in 2016: Here's Why

                                  by Arpita Dutt

                                  Was there any specific reason for the significantly lower number of drug approvals in 2016 compared to 2015?

                                    Impax (IPXL) Applies for Generic Aubagio; Sanofi Files Lawsuit

                                    by Zacks Equity Research

                                    Impax Laboratories, Inc. (IPXL) announced that it has filed an Abbreviated New Drug application (ANDA) with the FDA for a generic version of Sanofi's Aubagio (teriflunomide) tablets, 14 mg.

                                      Amgen's Repatha Wins Over Sanofi & Regeneron's Praluent

                                      by Zacks Equity Research

                                      The U.S. District Court in Delaware granted Amgen, Inc. (AMGN) permanent injunction against infringement by Sanofi and Regeneron of two patents owned by the former for Repatha.

                                        Arpita Dutt headshot

                                        Pharma Stock Roundup: PCSK9 Inhibitor Praluent in News, Allergan's Preliminary 2017 View

                                        by Arpita Dutt

                                        Key highlights this week include a court injunction blocking sales of PCSK9 inhibitor Praluent and preliminary guidance from Allergan (AGN).

                                          Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit

                                          by Zacks Equity Research

                                          Eli Lilly and Company's (LLY) animal health subsidiary Elanco, announced that it has closed the previously announced acquisition of German drugmaker Boehringer Ingelheim's Vetmedica U.S. pet vaccines unit.

                                            Sanofi (SNY) Closes Business Exchange Deal with Boehringer

                                            by Zacks Equity Research

                                            Sanofi (SNY) announced the closing of a previously announced deal to exchange its Merial animal health business with Boehringer Ingelheim's consumer healthcare (CHC) segment. The transaction was signed in Jun 2016.

                                              VIVUS (VVUS): Will Qsymia & Stendra Sales Improve in 2017?

                                              by Zacks Equity Research

                                              On Jan 3, we issued an updated report on VIVUS, Inc. (VVUS).

                                                Arpita Dutt headshot

                                                Regeneron vs. Vertex: Which Stock is a Better Pick?

                                                by Arpita Dutt

                                                Both Regeneron (REGN) and Vertex look set for a rebound in 2017 after a tough and challenging 2016.

                                                  J&J Resumes Talks with Actelion: Did Sanofi Just Lose Out?

                                                  by Zacks Equity Research

                                                  In an interesting turn of events, Johnson & Johnson (JNJ) announced that it is once again discussing a possible transaction with Swiss biotechnology company Actelion Ltd. (ALIOF).